Mn Services Vermogensbeheer B.V. Sells 11,900 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mn Services Vermogensbeheer B.V. cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 480,855 shares of the biopharmaceutical company’s stock after selling 11,900 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Gilead Sciences were worth $40,315,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the company. Sumitomo Life Insurance Co. grew its holdings in Gilead Sciences by 0.7% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company’s stock valued at $1,494,000 after purchasing an additional 117 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in Gilead Sciences by 3.9% during the 3rd quarter. Sivia Capital Partners LLC now owns 3,249 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 123 shares during the last quarter. Roberts Wealth Advisors LLC boosted its position in Gilead Sciences by 1.9% in the 3rd quarter. Roberts Wealth Advisors LLC now owns 7,035 shares of the biopharmaceutical company’s stock valued at $599,000 after buying an additional 130 shares during the period. Wagner Wealth Management LLC boosted its position in Gilead Sciences by 1.7% in the 3rd quarter. Wagner Wealth Management LLC now owns 8,026 shares of the biopharmaceutical company’s stock valued at $673,000 after buying an additional 135 shares during the period. Finally, Institute for Wealth Management LLC. boosted its position in Gilead Sciences by 1.9% in the 2nd quarter. Institute for Wealth Management LLC. now owns 7,551 shares of the biopharmaceutical company’s stock valued at $518,000 after buying an additional 142 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded up $0.58 during midday trading on Monday, reaching $90.09. The company had a trading volume of 1,690,158 shares, compared to its average volume of 6,997,873. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $90.71. The business’s 50-day simple moving average is $83.79 and its 200 day simple moving average is $74.21. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. The stock has a market cap of $112.16 billion, a P/E ratio of 109.16, a P/E/G ratio of 3.09 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. On average, analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,033,340 over the last quarter. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the subject of several research reports. Cantor Fitzgerald reissued a “neutral” rating and issued a $70.00 price objective on shares of Gilead Sciences in a research report on Monday, September 16th. Royal Bank of Canada reissued a “sector perform” rating and issued a $75.00 price objective on shares of Gilead Sciences in a research report on Tuesday, October 29th. Barclays boosted their price objective on shares of Gilead Sciences from $76.00 to $84.00 and gave the company an “equal weight” rating in a research report on Monday, October 7th. Wells Fargo & Company raised shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $78.00 to $100.00 in a research report on Monday, October 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Wednesday, October 9th. Ten analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $86.85.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.